UNDERSTANDING GIP
GIP and Weight Loss: A Physician's Guide to the GIP Receptor
You may have seen “GIP” mentioned alongside GLP-1 in discussions of Mounjaro, Zepbound, or newer investigational medications, without a clear explanation of what it actually is. This page explains GIP in plain terms and how it factors into your treatment options.
What Is GIP?
GIP stands for glucose-dependent insulinotropic polypeptide, a natural incretin hormone released by the intestines after eating. One of its best-established roles is helping stimulate insulin release when blood glucose is elevated. GIP receptors are also found in areas such as the brain and adipose tissue, and researchers continue to study how GIP signaling influences appetite, energy balance, and body weight.
What is a GIP Receptor Agonist?
A GIP receptor agonist activates the GIP receptor and produces some of the signaling effects associated with the natural GIP hormone. There is currently no FDA-approved GIP-only medication for weight management. In the FDA-approved medication tirzepatide, GIP receptor activation is combined with GLP-1 receptor activation.
Is There a GIP-Only Weight Loss Medication?
No. There is currently no FDA-approved weight loss medication that targets GIP by itself. Tirzepatide, the active ingredient in Mounjaro and Zepbound, activates both GIP and GLP-1 receptors. Retatrutide, which is still investigational, activates GIP, GLP-1, and glucagon receptors.
How Does Adding GIP Change the Effect?
The clearest evidence comes from a direct comparison of the medications. In the SURMOUNT-5 trial, adults with obesity but without type 2 diabetes who received tirzepatide lost an average of 20.2% of their body weight at 72 weeks, compared with 13.7% with semaglutide. Tirzepatide activates GIP and GLP-1 receptors, while semaglutide acts on GLP-1 alone. The trial shows an important difference between the medications, but it does not prove that GIP alone is responsible for the additional weight loss.
Who Might Benefit from a GIP-Targeting Medication?
A GIP-targeting medication such as tirzepatide may be considered for eligible patients based on the specific FDA-approved indication, medical history, weight-related health conditions, previous treatment experience, side-effect tolerance, current medications, and insurance coverage. You do not necessarily have to “fail” a GLP-1-only medication first unless your insurance plan or individual treatment situation requires it.
Cost & Insurance
Pricing depends on your insurance coverage, the specific product prescribed, your diagnosis, dose, and treatment plan. Coverage for Mounjaro and Zepbound can differ because they have different FDA-approved indications, and some plans may require prior authorization. Cost and available coverage are reviewed as part of your treatment planning. Many patients are able to use FSA or HSA funds toward eligible care expenses.
Can I get a GIP-targeting medication at New Viva MD?
New Viva MD Weight Loss provides physician-supervised evaluation for a GIP-targeting medication at our Chandler, Arizona clinic and by telehealth to patients throughout Arizona. Whether a GIP-targeting medication is prescribed depends on your medical history, diagnosis, and clinical evaluation by Dr. Surkunte — it is not guaranteed. We see patients in person in Chandler and remotely across Arizona, including Gilbert, Mesa, Tempe, Phoenix, Scottsdale, Queen Creek, and Ahwatukee.
Frequently Asked Questions
What does GIP stand for?
GIP stands for glucose-dependent insulinotropic polypeptide. It is an incretin hormone released after eating that helps stimulate insulin secretion when blood glucose is elevated. GIP also acts on receptors in other tissues, and its role in appetite and body-weight regulation is still being studied.
Is GIP the same as GLP-1?
No. GIP and GLP-1 are different but related incretin hormones released in response to food. They bind to different receptors and have overlapping but distinct effects on insulin, appetite, digestion, and metabolism.
Is there a medication that only targets GIP?
No. There is currently no FDA-approved weight loss medication that targets only the GIP receptor. Tirzepatide targets both GIP and GLP-1, while investigational retatrutide targets GIP, GLP-1, and glucagon.
Is tirzepatide a GIP medication?
Yes, but more precisely, tirzepatide is a dual GIP and GLP-1 receptor agonist. It is the active ingredient in both Mounjaro and Zepbound, which have different FDA-approved indications.
Does insurance cover GIP-targeting medications?
Coverage varies by the specific product, diagnosis, and insurance plan. Mounjaro and Zepbound both contain tirzepatide, but their approved indications are different, so insurance coverage and prior-authorization requirements may also differ.
Why Choose New Viva MD
Board Certified (ABIM), Diplomate (ABOM) — Dr. Arpita Surkunte personally evaluates every patient
Access to FDA-approved tirzepatide treatment when medically appropriate
LegitScript-certified — verify us
FDA-approved medications only. No compounded tirzepatide.
Disclaimer
This page is for educational purposes only and is not medical advice. Prescription medications require evaluation and approval by a licensed provider. Individual results vary. New Viva MD does not offer compounded semaglutide or compounded tirzepatide. Brand names are trademarks of their respective manufacturers; New Viva MD is not affiliated with, endorsed by, or sponsored by these manufacturers. Always consult your healthcare provider before starting, stopping, or changing any medication.